These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33390173)

  • 1. ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling.
    Tian H; Chou FJ; Tian J; Zhang Y; You B; Huang CP; Yeh S; Niu Y; Chang C
    J Exp Clin Cancer Res; 2021 Jan; 40(1):3. PubMed ID: 33390173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ASC-J9
    Lin W; Luo J; Sun Y; Lin C; Li G; Niu Y; Chang C
    Cancer Lett; 2018 Jul; 425():21-30. PubMed ID: 29425687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor (AR) degradation enhancer ASC-J9
    Cheng MA; Chou FJ; Wang K; Yang R; Ding J; Zhang Q; Li G; Yeh S; Xu D; Chang C
    Cancer Lett; 2018 Mar; 417():182-191. PubMed ID: 29203251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
    Wen S; Tian J; Niu Y; Li L; Yeh S; Chang C
    Cancer Lett; 2016 Jul; 376(2):377-86. PubMed ID: 27045473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.
    Wen S; Niu Y; Lee SO; Yeh S; Shang Z; Gao H; Li Y; Chou F; Chang C
    Mol Carcinog; 2016 Dec; 55(12):2278-2290. PubMed ID: 26894509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
    Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
    Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.
    Chou FJ; Chen Y; Chen D; Niu Y; Li G; Keng P; Yeh S; Chang C
    EBioMedicine; 2019 Feb; 40():504-516. PubMed ID: 30692044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.
    Yamashita S; Lai KP; Chuang KL; Xu D; Miyamoto H; Tochigi T; Pang ST; Li L; Arai Y; Kung HJ; Yeh S; Chang C
    Neoplasia; 2012 Jan; 14(1):74-83. PubMed ID: 22355276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
    Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
    J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals.
    Huang CP; Chen J; Chen CC; Liu G; Zhang Y; Messing E; Yeh S; Chang C
    J Exp Clin Cancer Res; 2019 Jun; 38(1):275. PubMed ID: 31234917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.
    Lin TH; Izumi K; Lee SO; Lin WJ; Yeh S; Chang C
    Cell Death Dis; 2013 Aug; 4(8):e764. PubMed ID: 23928703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression.
    Luo J; Tian J; Chou F; Lin C; Xing EZ; Zuo L; Niu Y; Yeh S; Chang C
    Cancer Lett; 2019 Mar; 444():35-44. PubMed ID: 30248372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
    Wang R; Lin W; Lin C; Li L; Sun Y; Chang C
    Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revealing the mechanism of ethyl acetate extracts of Semen Impatientis against prostate cancer based on network pharmacology and transcriptomics.
    Hu B; Wang C; Wu Y; Han C; Liu J; Chen R; Wang T
    J Ethnopharmacol; 2024 Aug; 330():118228. PubMed ID: 38643863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib with ASC-J9
    Xu J; Lin H; Li G; Sun Y; Shi L; Ma WL; Chen J; Cai X; Chang C
    Int J Cancer; 2017 Feb; 140(3):705-717. PubMed ID: 27668844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the effects and molecular mechanisms of dimethylcurcumin (ASC-J9) on androgen receptor-related diseases.
    Hu H; Zhou H; Xu D
    Chem Biol Drug Des; 2021 Apr; 97(4):821-835. PubMed ID: 33277796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New therapy with ASC-J9® to suppress the prostatitis via altering the cytokine CCL2 signals.
    Lin SJ; Chou FJ; Lin CY; Chang HC; Yeh S; Chang C
    Oncotarget; 2016 Oct; 7(41):66769-66775. PubMed ID: 27564257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.
    Shang Z; Li Y; Zhang M; Tian J; Han R; Shyr CR; Messing E; Yeh S; Niu Y; Chang C
    Mol Cancer Ther; 2015 Nov; 14(11):2586-94. PubMed ID: 26264279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASC-J9 suppresses renal cell carcinoma progression by targeting an androgen receptor-dependent HIF2α/VEGF signaling pathway.
    He D; Li L; Zhu G; Liang L; Guan Z; Chang L; Chen Y; Yeh S; Chang C
    Cancer Res; 2014 Aug; 74(16):4420-30. PubMed ID: 24924778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.